



DECEMBER 2011/JANUARY 2012

40 Years Later: "War" on Cancer Continues

In 1971, President Richard Nixon signed the National Cancer Act and declared war on cancer. Forty years later, what seems clear is that progress in treating cancer has been hard fought and there have been victories achieved with 12 million cancer survivors now living in the United States. To explore the progress of all cancer research and the victories we've seen through the years, visit the ASCO interactive timeline at CancerProgress.net. As the timeline overview shows, the death rate from all cancers has declined 22% for men and 14% for women from 1990 to 2008.

Today, the fight continues as we enter an era of personalized medicine and treatments become highly personalized based upon individual molecular profiles. Future progress is in the hands of those willing to join the research community, both physicians and patients, to partner in the battle. Too few patients participate in clinical trials to quickly develop and refine new treatments. Too few oncologists are willing to navigate the research maze littered with administrative and regulatory obstacles. After forty years, cancer research is primed for a revolutionary change. 2012 is the time to join and renew our commitment to conquering cancer.

[Back to top](#)

STUDY SPOTLIGHT

TRM is now enrolling, at multiple locations, the following study from Merrimack Pharmaceuticals:

"A Phase II Randomized Open Label Study of MM-121 in Combination with Paclitaxel versus Paclitaxel Alone in Patients with Platinum Resistant/Refractory Advanced Ovarian Cancers"

Up to 201 patients will be randomized (2:1) to receive MM-121 plus paclitaxel or paclitaxel alone.

Inclusion Criteria:

- Locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer

NEWS

INDUSTRY NEWS

Medpage Today [Washington Week: Medicare Cut Averted in Nick of Time](#) Congress voted December 23, 2011, to postpone Medicare cuts for doctors that were to take effect January 1, 2012. Instead, the 27% cut will be implemented March 1, 2012 unless a new deal is reached.

ASH Conference

[Study Favors As-Needed Treatment Over Maintenance Therapy for Patients with Follicular Lymphoma](#)

San Antonio Breast Cancer Symposium

[Dramatic CLEOPATRA Findings Support Addition of Pertuzumab to Regimen for HER2-Positive Metastatic Breast Cancer](#)

DID YOU KNOW

The Nobel Prize is awarded each year on the anniversary of Alfred Nobel's death, December 12. The 2011 recipients of the Nobel Prize in Physiology or Medicine were Bruce Beutler and Jules Hoffmann "for their discoveries concerning the activation of innate immunity" and Ralph Steinman "for his discovery of the dendritic cell and its role in adaptive immunity".

For information on their prize as well as others, visit NobelPrize.org


Unsubscribe

Click to instantly unsubscribe from this mailing list.

Send to a friend

Send this email to someone you think may be interested.

- Received at least one prior platinum based chemotherapy regimen
- Platinum-resistant or refractory
- Eligible for weekly paclitaxel
- Adequate liver and kidney function
- 18 years of age or above



Exclusion Criteria:

- Evidence of any other active malignancy
- History of severe allergic reactions to paclitaxel or other drugs formulated in Cremophor®EL
- NYHA Class III or IV congestive heart failure or LVEF less than normal, per institutional guidelines, or <55%, if not otherwise specified by institutional guidelines.

The above eligibility criteria are not all inclusive. Please [contact TRM](#) research personnel for further information or to refer a patient to a participating TRM investigator. You can also visit [ClinicalTrials.gov](#) for additional details.

[Back to top](#)

SITE SPOTLIGHT

In December we welcomed Hematology Oncology Medical Group (Orange County, CA) to TRM. HOMG is a nine (9) physician practice that has been conducting clinical trials in affiliation with St. Joseph Hospital and the National Cancer Institute Community Cancer Centers Program. The experienced study team is now partnered with TRM to expand their access to industry sponsored clinical trials targeting specific patient needs. The program will also bring HOMG patients access to early phase clinical trials. TRM welcomes our new partnership with HOMG!

[Back to top](#)

Happy New Year to All Our Partners in Research!

TRM would like to wish all our partners in research the very best for 2012!

[Back to top](#)

TRM and the TRM Logo are registered trademarks of **Translational Research Management**.
Translational Research Management - 11755 Wilshire Blvd Suite 2000, Los Angeles, CA 90025.
ph 424-208-8866 - fax 424-208-8867